Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165226 | 0.83 | HSD11B1 (0.59) | HSD11B1NR1H3 | |
| SCHEMBL4283778 | 0.77 | NR1H2 (0.31) | NR1H3 | |
| SCHEMBL9888655 | 0.76 | HSD11B1 (0.63) | HSD11B1NR1H3 | |
| SCHEMBL16463134 | 0.76 | — | — | |
| SCHEMBL28316979 | 0.76 | NR1I2 (0.32) | — | |
| SCHEMBL128375 | 0.76 | NR1H2 (0.50) | NR1H3AR | |
| SCHEMBL5354310 | 0.76 | HSD11B1 (0.63) | HSD11B1NR1H3 | |
| SCHEMBL107511 | 0.76 | PDE2A (0.47) | — | |
| SCHEMBL15459955 | 0.76 | HSD11B1 (0.53) | HSD11B1NR1H3 | |
| SCHEMBL9888614 | 0.76 | HSD11B1 (0.63) | HSD11B1NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373169-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2015-05-20 | — | — | EP | claimed |
| US-20140336169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-11-13 | — | — | US | claimed |
| US-8748607-B2 | Imidazopyrizine syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2014-06-10 | — | — | US | claimed |
| US-20130237521-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-8455493-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-06-04 | — | — | US | claimed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | claimed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-9796718-B2 | 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine | GILEAD CONNECTICUT, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3123864-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2716157-B1 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160031894-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-8455493-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8450321-B2 | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor | GILEAD CONNECTICUT, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | disclosed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031894-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HSD11B1 4159/4885NR1H3 3920/4885AR 4717/4885 |
| US-20120220582-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HSD11B1 4159/4885NR1H3 3920/4885AR 4717/4885 |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HSD11B1 4159/4885NR1H3 3920/4885AR 4717/4885 |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HSD11B1 4159/4885NR1H3 3920/4885AR 4717/4885 |
| US-20140336169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HSD11B1 4159/4885NR1H3 3920/4885AR 4717/4885 |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | HSD11B1 4159/4885NR1H3 3920/4885AR 4717/4885 |
| US-20130237521-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, ZAP70, BTK | HSD11B1 4133/4885NR1H3 3505/4885AR 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.